Posted by Michael Wonder on 06 Jul 2021
Opthea’s OPT-302 granted FDA fast track designation for wet age-related macular degeneration
6 July 2021 - FDA’s Fast Track Designation for OPT-302 offers benefits to expedite the OPT-302 Phase 3 clinical program and subsequent potential approval process.
Opthea is pleased to announce that the U.S. FDA has granted fast track designation for the company’s VEGF-C/-D ‘trap’ inhibitor, OPT-302, in combination with anti-VEGF- A therapy for the treatment of patients with neovascular (wet) age-related macular degeneration.
